Biontech enters clinic with mRNA-based malaria vaccine
The German company is putting all its knowledge from developing an mRNA-based Covid-19 vaccine to use to create a preventive treatment for the mosquito-borne disease.
by marketwire, translated by daniel pedersen
Biontech is initiating human trials with its mRNA-based malaria vaccine, and the first patient was dosed on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
GSK wins WHO seal of approval for malaria vaccine
For subscribers
